{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,4]],"date-time":"2026-05-04T08:38:31Z","timestamp":1777883911694,"version":"3.51.4"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T00:00:00Z","timestamp":1771200000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.jctube.2026.100592","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T00:40:28Z","timestamp":1771375228000},"page":"100592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["QT interval prolongation in patients receiving bedaquiline-based regimens for drug-resistant tuberculosis in Sub-Saharan Africa: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"43","author":[{"given":"Morrish Obol","family":"Okello","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ivaan","family":"Pitua","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"James Nelson","family":"Okema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Doris","family":"Ekwem","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Felix","family":"Bongomin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Olum","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jctube.2026.100592_b0005","unstructured":"World Health Organization. Global Tuberculosis Report. Geneva WHO 2021; 2021. https:\/\/www.who.int\/publications\/i\/item\/9789240037021."},{"key":"10.1016\/j.jctube.2026.100592_b0010","unstructured":"World Health Organization. Global tuberculosis report 2024; 2024. https:\/\/cdn.who.int\/media\/docs\/default-source\/global-tuberculosis-report-2024\/global-tb-report-2024_factsheet.pdf?sfvrsn=fee1c310_4&download=true."},{"key":"10.1016\/j.jctube.2026.100592_b0015","doi-asserted-by":"crossref","unstructured":"Sarathy JP, Gruber G, Dick T. Re-understanding the mechanisms of action of the anti-mycobacterial drug bedaquiline; 2019.","DOI":"10.3390\/antibiotics8040261"},{"key":"10.1016\/j.jctube.2026.100592_b0020","unstructured":"World Health Organization. The use of bedaquiline in the treatment of MDR TB; 2013."},{"key":"10.1016\/j.jctube.2026.100592_b0025","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02586-16","article-title":"Adverse effects and choice between the injectable agents amikacin and capreomycin in multidrug-resistant tuberculosis","volume":"61","author":"Arnold","year":"2017","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100592_b0030","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1056\/NEJMoa2117166","article-title":"A 24-week, all-oral regimen for rifampin-resistant tuberculosis","volume":"387","author":"Nyang\u2019wa","year":"2022","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jctube.2026.100592_b0035","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1136\/bjsm.2008.054734","article-title":"QTc: how long is too long?","volume":"43","author":"Johnson","year":"2009","journal-title":"Br J Sports Med"},{"key":"10.1016\/j.jctube.2026.100592_b0040","doi-asserted-by":"crossref","first-page":"1796","DOI":"10.3390\/s20061796","article-title":"ECG monitoring systems: review, architecture, processes, and key challenges","volume":"20","author":"Serhani","year":"2020","journal-title":"Sensors"},{"key":"10.1016\/j.jctube.2026.100592_b0045","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","volume":"75","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0050","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01181-2019","article-title":"A regimen containing bedaquiline and delamanid compared to bedaquiline in patients with drug-resistant tuberculosis","volume":"55","author":"Olayanju","year":"2020","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jctube.2026.100592_b0055","article-title":"HIV and body mass index are associated with prolonged corrected QT interval among people with drug-resistant tuberculosis on bedaquiline-containing regimen in Uganda","volume":"13","author":"Lodiong","year":"2024","journal-title":"IJID Reg"},{"key":"10.1016\/j.jctube.2026.100592_b0060","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1016\/S1473-3099(18)30100-2","article-title":"Early safety and efficacy of the combination of bedaquiline and delamanid for the treatment of patients with drug-resistant tuberculosis in Armenia, India, and South Africa: a retrospective cohort study","volume":"18","author":"Ferlazzo","year":"2018","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0065","doi-asserted-by":"crossref","DOI":"10.1093\/ofid\/ofab413","article-title":"QT interval prolongation in people treated with bedaquiline for drug-resistant tuberculosis under programmatic conditions: a retrospective cohort study","volume":"8","author":"Isralls","year":"2021","journal-title":"Open Forum Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0070","doi-asserted-by":"crossref","first-page":"349","DOI":"10.4103\/ijmy.ijmy_178_22","article-title":"Scoping review","volume":"11","author":"Putra","year":"2022","journal-title":"Int J Mycobacteriol"},{"key":"10.1016\/j.jctube.2026.100592_b0075","unstructured":"Liang F, Tantan R, Peize Z, Shuihua L. Interpretation of WHO consolidated guidelines on tuberculosis, Module 4 :treatment-drug-resistant tuberculosis treatment 2022 update 2023; 45. https:\/\/doi.org\/10.19982\/j.issn.1000-6621.20220523."},{"key":"10.1016\/j.jctube.2026.100592_b0105","doi-asserted-by":"crossref","first-page":"62","DOI":"10.4314\/ahs.v24i2.8","article-title":"Adverse effects associated with Kanamycin, Amikacin, Capreomycin and Bedaquiline -a VigiAccessTM study","volume":"24","author":"Singh","year":"2024","journal-title":"Afr Health Sci"},{"key":"10.1016\/j.jctube.2026.100592_b0110","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0236264","article-title":"Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: a retrospective cohort study","volume":"15","author":"Kashongwe","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.jctube.2026.100592_b0115","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1093\/inthealth\/ihac016","article-title":"Definitive outcomes in patients with rifampicin-resistant tuberculosis treated in Niger from 2012 to 2019: a retrospective cohort study","volume":"15","author":"Souleymane","year":"2023","journal-title":"Int Health"},{"key":"10.1016\/j.jctube.2026.100592_b0120","doi-asserted-by":"crossref","first-page":"1307","DOI":"10.1093\/cid\/ciac176","article-title":"Safety and effectiveness outcomes from a 14-country cohort of patients with multi-drug resistant tuberculosis treated concomitantly with bedaquiline, delamanid, and other second-line drugs","volume":"75","author":"Huerga","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0125","article-title":"Adverse effects of bedaquiline in patients with extensively drug-resistant tuberculosis","volume":"35","author":"Gaida","year":"2020","journal-title":"South African J Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0130","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1097\/QAI.0000000000003150","article-title":"Decentralized, integrated treatment of RR\/MDR-TB and HIV using a bedaquiline-based, short-course regimen is effective and associated with improved HIV disease control","volume":"92","author":"Govender","year":"2023","journal-title":"JAIDS J Acquir Immune Defic Syndr"},{"key":"10.1016\/j.jctube.2026.100592_b0135","doi-asserted-by":"crossref","DOI":"10.1128\/aac.01448-22","article-title":"QT interval prolongation with one or more QT-prolonging agents used as part of a multidrug regimen for rifampicin-resistant tuberculosis treatment: findings from two pediatric studies","volume":"67","author":"Ali","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100592_b0140","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1093\/cid\/ciab335","article-title":"Effectiveness and cardiac safety of bedaquiline-based therapy for drug-resistant tuberculosis: a prospective cohort study","volume":"73","author":"Brust","year":"2021","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0145","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01528-2018","article-title":"High treatment success rate for multidrug-resistant and extensively drug-resistant tuberculosis using a bedaquiline-containing treatment regimen","volume":"52","author":"Ndjeka","year":"2018","journal-title":"Eur Respir J"},{"key":"10.1016\/j.jctube.2026.100592_b0150","doi-asserted-by":"crossref","first-page":"979","DOI":"10.5588\/ijtld.14.0944","article-title":"Treatment of drug-resistant tuberculosis with bedaquiline in a high HIV prevalence setting: an interim cohort analysis","volume":"19","author":"Ndjeka","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0155","unstructured":"UNAIDS. UNAIDS data 2021. UNAIDS Jaint United Nationns Program HIV\/AIDS 2021:1\u201138."},{"key":"10.1016\/j.jctube.2026.100592_b0160","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2021-054397","article-title":"Determinants of accessing healthcare in Sub-Saharan Africa: a mixed-effect analysis of recent Demographic and Health surveys from 36 countries","volume":"12","author":"Tessema","year":"2022","journal-title":"BMJ Open"},{"key":"10.1016\/j.jctube.2026.100592_b0165","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.jinf.2018.08.003","article-title":"Outcomes of patients with drug-resistant-tuberculosis treated with bedaquiline-containing regimens and undergoing adjunctive surgery","volume":"78","author":"Borisov","year":"2019","journal-title":"J Infect"},{"key":"10.1016\/j.jctube.2026.100592_b0170","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1016\/j.jmii.2023.04.009","article-title":"Comparative safety of bedaquiline and delamanid in patients with multidrug resistant tuberculosis: a nationwide retrospective cohort study","volume":"56","author":"Kim","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"10.1016\/j.jctube.2026.100592_b0175","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1186\/s12879-022-07861-x","article-title":"Bedaquiline safety, efficacy, utilization and emergence of resistance following treatment of multidrug-resistant tuberculosis patients in South Africa: a retrospective cohort analysis","volume":"22","author":"Pai","year":"2022","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0180","doi-asserted-by":"crossref","first-page":"459","DOI":"10.3851\/IMP3335","article-title":"Abnormal QTc syndrome in HIV-infected patients: a systematic review of prevalence and risk factors","volume":"24","author":"Chastain","year":"2019","journal-title":"Antivir Ther"},{"key":"10.1016\/j.jctube.2026.100592_b0185","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.02687-20","article-title":"Effect of clofazimine concentration on QT prolongation in patients treated for tuberculosis","volume":"65","author":"Abdelwahab","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100592_b0085","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1473-3099(20)30770-2","article-title":"QT effects of bedaquiline, delamanid, or both in patients with rifampicin-resistant tuberculosis: a phase 2, open-label, randomised, controlled trial","volume":"21","author":"Dooley","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0090","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1002\/cpt.2685","article-title":"Assessing prolongation of the corrected QT interval with bedaquiline and delamanid coadministration to predict the cardiac safety of simplified dosing regimens","volume":"112","author":"Tanneau","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.jctube.2026.100592_b0095","doi-asserted-by":"crossref","DOI":"10.1128\/aac.00536-24","article-title":"How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial","volume":"68","author":"Motta","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.jctube.2026.100592_b0100","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1186\/s12879-019-4197-7","article-title":"Adverse drug reactions in South African patients receiving bedaquiline-containing tuberculosis treatment: an evaluation of spontaneously reported cases","volume":"19","author":"Jones","year":"2019","journal-title":"BMC Infect Dis"},{"key":"10.1016\/j.jctube.2026.100592_b0190","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1186\/s12913-018-3426-x","article-title":"Capacity of Ugandan public sector health facilities to prevent and control non-communicable diseases: an assessment based upon WHO-PEN standards","volume":"18","author":"Rogers","year":"2018","journal-title":"BMC Health Serv Res"}],"container-title":["Journal of Clinical Tuberculosis and Other Mycobacterial Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000148?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405579426000148?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T02:03:59Z","timestamp":1777601039000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405579426000148"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":37,"alternative-id":["S2405579426000148"],"URL":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100592","relation":{},"ISSN":["2405-5794"],"issn-type":[{"value":"2405-5794","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"QT interval prolongation in patients receiving bedaquiline-based regimens for drug-resistant tuberculosis in Sub-Saharan Africa: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Tuberculosis and Other Mycobacterial Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jctube.2026.100592","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100592"}}